Linezolid Alone or Combined With Carbapenem Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Ventilator-associated Pneumonia

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

As previous studies showed that the synergy between linezolid and carbapenem in vitro and in vivo (animal studies), our study is aim to investigate the activity of linezolid, alone and in combination with carbapenem against methicillin-resistant Staphylococcus aureus (MRSA) in ventilator-associated pneumonia (VAP) patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ruijin Hospital
• Collaborator: Pfizer
• Treatments: Cilastatin; Imipenem; Linezolid; Methicillin

Criteria

Inclusion Criteria:

• Pneumonia, Ventilator-associated

• the presence of new or persistent radiographic features

• fever higher than 38°C

• leukocytosis (≥11.0 ×109/L) or neutropenia (≤3.5×109/L)

• purulent endotracheal

• increasing oxygen requirements

• Endotracheal aspiration culture show methicillin-resistant S. aureus positive

Exclusion Criteria:

• immunocompromised patients (postorgan transplantation or human immunodeficiency virus-infected or neutropenic [≤1×109/L absolute neutrophils], or patients receiving corticosteroids >20 mg/d for 6 months)

• colonized chronically with methicillin-resistant S. aureus

• pregnancy

• endotracheal aspiration culture showed no MRSA